Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Business Segments — Merger-related

Similar metrics at other companies

NSA
NSAReportable Segment — Merger related costs
$9.98M
Pacific Biosciences of California logo
PACBReportable Segment — Merger-related expenses
$0
Norfolk Southern logo
NSCReportable Segment — Merger-related expenses
$51M
Albertsons Companies logo
ACIReportable Segment — Noncash Merger Related Costs
$41.6M+119%
Ginkgo Bioworks logo
DNAReportable Segment — Merger and acquisition related expense (income)
$1.11M+131%
CNB Financial logo
CCNEReportable Segment — Merger and integration costs
$0-100%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.3B+320%
Enterprise value$1.32B+474%

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept inbx:GeneralAndAdministrativeExpenseMergerRelated.

The source filing: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026.

Filed
Mar 19, 2026, 4:00 PM EDT
Fiscal year
FY2025
Accession
0002007919-26-000006
Line itemYEAR ENDEDDECEMBER 31, 2025YEAR ENDEDDECEMBER 31, 2024
Equipment, depreciation, and facility10,2279,693
Other research and development12,50017,952
General and administrative expense
Merger-related68,061
Personnel14,48137,649
Other general and administrative8,81622,195
Other income (expense)(5,028)(2,476)
Other segment items(1)2,021,498

Item 8. Financial Statements and Supplementary Data.

FAQ

What is Inhibrx Biosciences, Inc.'s business segments — merger-related?
Inhibrx Biosciences, Inc. (INBX) reported business segments — merger-related of $0 in Q4 2025.
How has Inhibrx Biosciences, Inc.'s business segments — merger-related changed year-over-year?
Inhibrx Biosciences, Inc.'s business segments — merger-related decreased by 100.0% year-over-year, from $17.02M to $0.
What is the long-term trend for Inhibrx Biosciences, Inc.'s business segments — merger-related?
Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s business segments — merger-related has grown at a -100.0% compound annual growth rate (CAGR), from $36K to $0.
What does business segments — merger-related mean?
Represents non-recurring costs directly attributable to merger, acquisition, or corporate restructuring activities within the segment. Monitoring this metric helps investors distinguish between core operational performance and one-time transaction-related financial impacts.

Ask your AI about Inhibrx Biosciences, Inc.'s business segments — merger-related.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude